Canmab 150mg Injection

About

Canmab 150mg Injection is a monoclonal antibody therapy, likely targeting specific receptors on cancer cells, such as HER2. It works by binding to these receptors, inhibiting cell growth and proliferation, and marking cancer cells for destruction by the immune system. This targeted approach helps to selectively attack cancer cells while minimizing harm to healthy cells, making it a crucial component in the treatment of certain types of cancer.

Administered intravenously, Canmab is often used in combination with chemotherapy or as a standalone therapy, depending on the specific cancer type and stage. Its mechanism of action provides a more precise therapeutic effect compared to traditional cytotoxic agents, contributing to improved patient outcomes in HER2-positive malignancies.

Uses

• HER2-positive breast cancer (early or metastatic)
• HER2-positive metastatic gastric cancer
• HER2-positive gastroesophageal junction adenocarcinoma
• Adjuvant therapy for HER2-positive early breast cancer

Directions For Use

Canmab 150mg Injection is administered intravenously by a healthcare professional. Dosage and frequency are determined by the patient's weight and specific cancer protocol.

Benefits

• Targeted therapy for HER2-positive cancers
• Improves progression-free and overall survival
• Can be used in combination with chemotherapy
• Reduces risk of cancer recurrence
• Generally well-tolerated compared to traditional chemotherapy
• Specific mechanism of action

Side Effects

• Infusion-related reactions (fever, chills, headache)
• Cardiotoxicity (heart problems, e.g., decreased ejection fraction)
• Diarrhea
• Nausea
• Fatigue
• Rash
• Myalgia (muscle pain)
• Arthralgia (joint pain)
• Anemia
• Neutropenia
• Peripheral neuropathy
• Cough

Safety Measures

• Alcohol - No specific interaction, but alcohol should be avoided or limited during cancer treatment due to general health considerations.
• Pregnancy - Contraindicated in pregnancy due to potential fetal harm, including oligohydramnios and fetal lung hypoplasia.
• Breastfeeding - Not recommended during breastfeeding as the drug may pass into breast milk and harm the infant.
• Liver - Use with caution in patients with pre-existing liver conditions; monitor liver function tests regularly.
• Kidney - Use with caution in patients with pre-existing kidney conditions; monitor renal function tests regularly.
• Lung - Monitor for pulmonary toxicity, including interstitial pneumonitis, especially in patients with pre-existing lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.